Abstract:Background: Randomized studies have shown that the addition of weekly cetuximab to FOLFOX or FOLFIRI improves clinical outcome in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC). This Asia-Pacific multicenter non-randomized phase II study investigated the efficacy and safety of both FOLFOX and FOLFIRI in combination with every 2 weeks cetuximab as first-line therapy in patients with KRAS wild-type mCRC. Methods: Eligible patients received every 2 weeks cetuximab (day 1, 500 mg/m2 every 14 days) with, based on investigator's choice, either FOLFOX (oxaliplatin 100 mg/m2, folinic acid [FA] 200 mg/m2 L-form or 400 mg/m2 racemic, then 5-fluorouracil [5-FU], as a 400 mg/m2 iv bolus and a 2400 mg/m2 infusion over 46 h) or FOLFIRI (irinotecan 180 mg/m2, FA 200 mg/m2 L-form, or 400 mg/m2 racemic, then 5-FU, as a 400 mg/m2 iv bolus and a 2400 mg/m2 infusion over 46 h). Study treatment was continued until disease progression, the occurrence of unacceptable toxicity or consent withdrawal. The primary endpoint was tumor response; assessed radiologically (RECIST 1.0) every 8 weeks. Results: Data cut-off was 86 weeks after the date of the last patient included. The intention to treat (ITT)/safety population comprised 289 patients; 65.1% received FOLFOX plus cetuximab and 34.9% FOLFIRI plus cetuximab. Baseline characteristics were generally well balanced between treatment groups. However, leukocyte count >10000/mm3 was more frequent (16.5% vs 7.9%) and prior adjuvant treatment less frequent (21.3% vs 46.5%) in patients receiving FOLFOX plus cetuximab. A best overall response (complete + partial) rate of 58.8% and a median progression-free survival (mPFS) time of 11.1 months were observed in the combined ITT population (Table). 70.9% of patients showed ≥20% reduction in tumor diameter at 8 weeks from baseline. A post-hoc analysis showed a mPFS time of 12.7 months for this group. The overall R0 resection rate in the ITT population was 10.0%. Survival data are not yet mature. Cetuximab dose intensity was >80% in 77.7% of patients in the FOLFOX plus cetuximab group and 74.3% of patients in the FOLFIRI plus cetuximab group. The most frequent grade 3/4 adverse events (reported for >10% of patients in either arm) were neutropenia, diarrhea, hypokalemia, neuropathy (FOLFOX plus cetuximab group only) and skin reactions. Conclusion: In this study population from the Asia-Pacific region, first-line treatment with chemotherapy plus cetuximab was active and well-tolerated. Efficacy and safety profiles of every 2 weeks cetuximab combined with FOLFOX or FOLFIRI were similar to those reported for either chemotherapy plus weekly cetuximab in pivotal studies.Table Open table in a new tab

Impact of Primary Tumor Side (TS) on Outcomes of Once-Every-2-weeks (q2w) Cetuximab + First-Line (1L) FOLFOX or FOLFIRI in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) in the Phase 2 APEC Trial.

Impact Of Primary Tumor Side On Outcomes Of Every-2-Weeks (Q2w) Cetuximab Plus First-Line Folfox Or Folfiri In Patients With Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) In The Phase 2 Apec Trial.

Phase II APEC Trial: the Impact of Primary Tumor Side on Outcomes of First‐line Cetuximab Plus FOLFOX or FOLFIRI in Patients with RAS Wild‐type Metastatic Colorectal Cancer

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

China Special Issue on Gastrointestinal Tumors‐cetuximab Retreatment Plus Camrelizumab and Liposomal Irinotecan in Patients with RAS Wild‐type Metastatic Colorectal Cancer: Cohort B of the Phase II CRACK Study

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Impact of Primary Tumour Side on 3-Year Survival Outcomes of First-Line (1L) FOLFOX-4 ± Cetuximab in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) in the Phase III TAILOR Trial

Efficacy and Safety of Every-2-weeks Cetuximab Combined with FOLFOX or FOLFIRI As First-Line Therapy in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (mcrc): an Asia-Pacific Nonrandomized Phase II Study (APEC).

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line Folfox or Folfiri in Patients with Kras or All Ras Wild-Type Metastatic Colorectal Cancer: the Phase 2 Apec Study

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

The Optimal First-Line Treatment for Patients with Left-Sided RAS Wild-Type Metastatic Colorectal Cancer: Double-drug Regimen or Triple-Drug Regimen Therapy

Impact of Primary Tumor Side on Clinical Outcomes of First-Line Cetuximab Plus FOLFOX-4 in RAS Wild-Type Metastatic Colorectal Cancer.

Patients with RAS Wild-Type Right-Sided Unresectable Liver-Confined Mcrc Also Benefit from Cetuximab Plus Chemotherapy in First-Line Treatment

Final Analysis of the Phase 2 Apec Study: Overall Survival (os) Data and Biomarker Subanalyses for First-Line Folfox or Folfiri with Cetuximab (cet) Once Every 2 Weeks in Patients (pts) with Kras or Ras (kras and Nras, Exons 2-4) Wild-Type (wt) Metastatic Colorectal Cancer (Mcrc).

First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study

Impact of Cetuximab Sequence on Progress-Free Survival (PFS) and Overall Survival (OS) in Patients with RAS Wild-Type Metastatic Colorectal Cancer (mcrc): A Real-World Study.

Quality of Life (qol) Analyses in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) Treated with First-Line FOLFOX-4 ± Cetuximab in the Phase 3 TAILOR Trial

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab.

Right- and Left-Sided Colorectal Cancers Respond Differently to Cetuximab

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF -mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI ☆